查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152395

孤兒藥市場規模、佔有率和趨勢分析報告：按藥物類型、疾病、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Orphan Drugs Market Size, Share & Trends Analysis Report By Drug Type(Conventional Biologics, Cell Therapies), By Disease Type, By Route of Administration, By Distribution Channel,By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

孤兒藥市場概述

預計到 2025 年，全球孤兒藥市場價值將達到 2,201 億美元，從 2026 年的 2,381 億美元成長到 2033 年的 4,349 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 9.0%。

北美市場處於領先地位，預計到 2025 年將佔據最大的銷售佔有率，達到 41.2%。在有利的監管政策、醫學研究的不斷進步以及對罕見疾病治療方法研發日益重視的推動下，該行業正在不斷發展壯大。

由於核准治療方案有限或根本沒有，許多罕見疾病仍然迫切需要新的治療方法。市場獨佔權、稅收減免、費用降低和加速法規核准等激勵獎勵鼓勵製藥和生技公司投資研發孤兒藥。基因研究、生技藥品、基因療法和細胞療法的進步正在推動多種罕見疾病標靶治療的開發。此外，疾病認知度的提高、基因檢測的普及、患者權益倡導組織的積極活動以及篩檢計畫的擴展，都提高了患者獲得早期診斷和治療的機會。然而，企業仍面臨研發成本高、病患群體規模小、生產流程複雜以及價格壓力等挑戰。這些因素持續影響孤兒藥市場的投資決策和競爭格局。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：孤兒藥市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：孤兒藥市場：依藥物類型分類的商業分析

  • 按藥物類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按藥物類型分類，2021-2033 年
  • 小分子藥物
  • 傳統生物製藥
  • 基因治療
  • 細胞療法
  • 其他

第5章：孤兒藥市場：依疾病類型分類的商業分析

  • 按疾病類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按疾病類型分類，2021-2033 年
  • 罕見遺傳性疾病
  • 罕見癌症
  • 罕見的先天性和發育性疾病
  • 罕見自體免疫疾病和免疫介導性疾病
  • 罕見感染疾病
  • 罕見後天疾病
  • 其他

第6章：孤兒藥市場：依給藥途徑進行業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 口服
  • 靜脈
  • 皮下
  • 肌肉內部
  • 鞘內給藥
  • 眼內/眼科
  • 吸入
  • 其他

第7章：孤兒藥市場：依通路進行業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 專科藥房
  • 零售藥房
  • 郵購/網路藥房
  • 其他

第8章：孤兒藥市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Johnson & Johnson
    • AstraZeneca
    • Roche
    • Novartis
    • Vertex Pharmaceuticals
    • Sanofi
    • Amgen
    • Merck & Co.
    • Bristol Myers Squibb
    • Pfizer
Product Code: GVR-4-68041-054-7

Orphan Drugs Market Summary

The global orphan drugs market size was valued at USD 220.1 billion in 2025 and is projected to grow from USD 238.1 billion in 2026 to USD 434.9 billion by 2033, at a CAGR of 9.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The industry is growing due to the increasing focus on developing treatments for rare diseases, supported by favorable regulatory policies and continuous advances in medical research.

Many rare diseases still have limited or no approved treatment options, creating a strong need for new therapies. Incentives such as market exclusivity, tax benefits, fee reductions, and faster regulatory review encourage pharmaceutical and biotechnology companies to invest in orphan drug development. Progress in genetic research, biologics, gene therapy, and cell therapy has improved the development of targeted treatments for several rare conditions. In addition, better disease awareness, wider use of genetic testing, patient advocacy efforts, and expanded screening programs are helping improve early diagnosis and access to treatment. At the same time, companies continue to face challenges related to high research and development costs, small patient populations, complex manufacturing processes, and pricing pressures. These factors continue to shape investment decisions and competition in the orphan drugs market.

Global Orphan Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global orphan drugs market report based on drug type, disease type, route of administration, distribution channel, and region:

  • Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Small Molecule Drugs
  • Conventional Biologics
  • Gene Therapies
  • Cell Therapies
  • Others
  • Disease Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Rare Genetic & Inherited Disorders
  • Rare Cancers
  • Rare Congenital & Developmental Disorders
  • Rare Autoimmune & Immune-Mediated Disorders
  • Rare Infectious Diseases Rare Acquired Disorders
  • Rare Acquired Disorders
  • Others
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Intrathecal
  • Intraocular / Ophthalmic
  • Inhalation
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Mail-Order / Online Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
    • 1.2.2. Disease Type
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Orphan Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Orphan Drugs Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Billion)
  • 4.4. Small Molecule Drugs
    • 4.4.1. Small Molecule Drugs Market, 2021 - 2033 (USD Billion)
  • 4.5. Conventional Biologics
    • 4.5.1. Conventional Biologics Market, 2021 - 2033 (USD Billion)
  • 4.6. Gene Therapies
    • 4.6.1. Gene Therapies Market, 2021 - 2033 (USD Billion)
  • 4.7. Cell Therapies
    • 4.7.1. Cell Therapies Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Orphan Drugs Market: Disease Type Business Analysis

  • 5.1. Disease Type Market Share, 2025 & 2033
  • 5.2. Disease Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Billion)
  • 5.4. Rare Genetic & Inherited Disorders
    • 5.4.1. Rare Genetic & Inherited Disorders Market, 2021 - 2033 (USD Billion)
  • 5.5. Rare Cancers
    • 5.5.1. Rare Cancers Market, 2021 - 2033 (USD Billion)
  • 5.6. Rare Congenital & Developmental Disorders
    • 5.6.1. Rare Congenital & Developmental Disorders Market, 2021 - 2033 (USD Billion)
  • 5.7. Rare Autoimmune & Immune-Mediated Disorders
    • 5.7.1. Rare Autoimmune & Immune-Mediated Disorders Market, 2021 - 2033 (USD Billion)
  • 5.8. Rare Infectious Diseases
    • 5.8.1. Rare Infectious Diseases Market, 2021 - 2033 (USD Billion)
  • 5.9. Rare Acquired Disorders
    • 5.9.1. Rare Acquired Disorders Market, 2021 - 2033 (USD Billion)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Orphan Drugs Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
  • 6.5. Intravenous
    • 6.5.1. Intravenous Market, 2021 - 2033 (USD Billion)
  • 6.6. Subcutaneous
    • 6.6.1. Subcutaneous Market, 2021 - 2033 (USD Billion)
  • 6.7. Intramuscular
    • 6.7.1. Intramuscular Market, 2021 - 2033 (USD Billion)
  • 6.8. Intrathecal
    • 6.8.1. Intrathecal Market, 2021 - 2033 (USD Billion)
  • 6.9. Intraocular / Ophthalmic
    • 6.9.1. Intraocular / Ophthalmic Market, 2021 - 2033 (USD Billion)
  • 6.10. Inhalation
    • 6.10.1. Inhalation Market, 2021 - 2033 (USD Billion)
  • 6.11. Others
    • 6.11.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Orphan Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Specialty Pharmacies
    • 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.7. Mail-Order / Online Pharmacies
    • 7.7.1. Mail-Order / Online Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.8. Others
    • 7.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Orphan Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Orphan Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Johnson & Johnson
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AstraZeneca
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Roche
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Novartis
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Vertex Pharmaceuticals
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Sanofi
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Amgen
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Merck & Co.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Bristol Myers Squibb
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Pfizer
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global orphan drugs market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 5 Global orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 6 Global orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 7 Global orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America orphan drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 10 North America orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 11 North America orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 12 North America orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 U.S. orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 14 U.S. orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 15 U.S. orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 16 U.S. orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 18 Canada orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 19 Canada orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 20 Canada orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 22 Mexico orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 23 Mexico orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 24 Mexico orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe orphan drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 27 Europe orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 28 Europe orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 29 Europe orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 31 UK orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 32 UK orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 33 UK orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 35 Germany orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 36 Germany orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 37 Germany orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 39 France orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 40 France orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 41 France orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 43 Italy orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 44 Italy orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 45 Italy orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 47 Spain orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 48 Spain orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 49 Spain orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 51 Norway orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 52 Norway orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 53 Norway orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 55 Denmark orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 56 Denmark orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 57 Denmark orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 59 Sweden orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 60 Sweden orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 61 Sweden orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific orphan drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 68 Japan orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 69 Japan orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 70 Japan orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 72 China orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 73 China orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 74 China orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 76 India orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 77 India orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 78 India orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 79 Australia orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 80 Australia orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 81 Australia orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 82 Australia orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 84 South Korea orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 85 South Korea orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 86 South Korea orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 88 Thailand orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 89 Thailand orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 90 Thailand orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America orphan drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 93 Latin America orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 94 Latin America orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 95 Latin America orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 97 Brazil orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 98 Brazil orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 99 Brazil orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 101 Argentina orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 102 Argentina orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 103 Argentina orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa orphan drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 110 South Africa orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 111 South Africa orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 112 South Africa orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 118 UAE orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 119 UAE orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 120 UAE orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait orphan drugs market, by drug type, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait orphan drugs market, by disease type, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait orphan drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait orphan drugs market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Orphan drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Orphan drugs market dynamics
  • Fig. 11 Orphan drugs market: Porter's five forces analysis
  • Fig. 12 Orphan drugs market: PESTLE analysis
  • Fig. 13 Drug type market, 2021 - 2033 (USD Billion)
  • Fig. 14 Small molecule drugs market, 2021 - 2033 (USD Billion)
  • Fig. 15 Conventional Biologics market, 2021 - 2033 (USD Billion)
  • Fig. 16 Gene therapies market, 2021 - 2033 (USD Billion)
  • Fig. 17 Cell therapies market, 2021 - 2033 (USD Billion)
  • Fig. 18 Others market, 2021 - 2033 (USD Billion)
  • Fig. 19 Disease type market, 2021 - 2033 (USD Billion)
  • Fig. 20 Rare genetic & inherited disorders market, 2021 - 2033 (USD Billion)
  • Fig. 21 Rare cancers market, 2021 - 2033 (USD Billion)
  • Fig. 22 Rare congenital & developmental disorders market, 2021 - 2033 (USD Billion)
  • Fig. 23 Rare autoimmune & immune-mediated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 24 Rare infectious diseases market, 2021 - 2033 (USD Billion)
  • Fig. 25 Rare acquired disorders market, 2021 - 2033 (USD Billion)
  • Fig. 26 Others market, 2021 - 2033 (USD Billion)
  • Fig. 27 Route of administration market, 2021 - 2033 (USD Billion)
  • Fig. 28 Oral market, 2021 - 2033 (USD Billion)
  • Fig. 29 Intravenous market, 2021 - 2033 (USD Billion)
  • Fig. 30 Subcutaneous market, 2021 - 2033 (USD Billion)
  • Fig. 31 Intramuscular market, 2021 - 2033 (USD Billion)
  • Fig. 32 Intrathecal market, 2021 - 2033 (USD Billion)
  • Fig. 33 Intraocular/ophthalmic market, 2021 - 2033 (USD Billion)
  • Fig. 34 Inhalation market, 2021 - 2033 (USD Billion)
  • Fig. 35 Others market, 2021 - 2033 (USD Billion)
  • Fig. 36 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 37 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 38 Specialty pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 39 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 40 Mail-order/online pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 41 Others market, 2021 - 2033 (USD Billion)
  • Fig. 42 Orphan drugs market revenue, by region
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 45 U.S. country dynamics
  • Fig. 46 U.S. orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 47 Canada country dynamics
  • Fig. 48 Canada orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 49 Mexico country dynamics
  • Fig. 50 Mexico orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 51 Europe orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 52 UK country dynamics
  • Fig. 53 UK orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 54 Germany country dynamics
  • Fig. 55 Germany orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 56 France country dynamics
  • Fig. 57 France orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 58 Italy country dynamics
  • Fig. 59 Italy orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 60 Spain country dynamics
  • Fig. 61 Spain orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 62 Norway country dynamics
  • Fig. 63 Norway orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 64 Sweden country dynamics
  • Fig. 65 Sweden orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 66 Denmark country dynamics
  • Fig. 67 Denmark orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 68 Asia Pacific orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 69 Japan country dynamics
  • Fig. 70 Japan orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 71 China country dynamics
  • Fig. 72 China orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 73 India country dynamics
  • Fig. 74 India orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 75 Australia country dynamics
  • Fig. 76 Australia orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 77 South Korea country dynamics
  • Fig. 78 South Korea orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 79 Thailand country dynamics
  • Fig. 80 Thailand orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 81 Latin America orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 82 Brazil country dynamics
  • Fig. 83 Brazil orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 84 Argentina country dynamics
  • Fig. 85 Argentina orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 86 MEA orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 87 South Africa country dynamics
  • Fig. 88 South Africa orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 89 Saudi Arabia country dynamics
  • Fig. 90 Saudi Arabia orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 91 UAE country dynamics
  • Fig. 92 UAE orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 93 Kuwait country dynamics
  • Fig. 94 Kuwait orphan drugs market, 2021 - 2033 (USD Billion)
  • Fig. 95 Company categorization
  • Fig. 96 Company market position analysis
  • Fig. 97 Strategic framework